PIK3C3 promotes <i>Shigella flexneri</i> cell-to-cell spread through resolution of VLPs into DMVs. by Steven J. Rolland (21376879)

Changes in approach speed’s effect size (i.e., the phi-index, or <i>f 2</i>) with different slopes for the FID and approach speed relationship for three different models potentiall... by Ryan B. Lunn (12536881)

DJ-1 knockdown in BV-2 microglia cells enhances LPS-induced death of co-cultured SH-SY5Y neuronal cells. by Chia-Hung Chien (19355)

“…Cell viability of SH-SY5Y was evaluated by using MTT assay (A) and methylene blue assay (B). …”

Foxf1 promotes expression of a Wnt signaling reporter. by Ugo Coppola (3524945)

“…<i>Xla-Sia</i>:<i>GFP</i> embryos at 34 hpf. (<b>A’-C’</b>) <i>7xTcf</i>.<i>Xla-Sia</i>:<i>GFP</i> (green), (<b>A”-C”</b>) Mhc (red), and (<b>A”’-C”’</b>) Amhc (blue). …”

Effect of dynamin inhibitors on microtubule morphology and tubulin acetylation. by Maaike Kockx (154125)

Functional analyses of ARHGAP11A-knockdown HCT116 human colon cancer cells. by Yoshinori Kagawa (503599)

“…(I) <i>In vivo</i> siRNA treatment of HCT116 tumors. Control HCT116 cells (5.0×10⁶) were implanted into NOD/SCID mice, and 1 week later were treated with PBS (<i>black filled</i> circles), atelocollagen (<i>black filled</i> triangles), scrambled control siRNA plus atelocollagen (<i>black filled</i> squares), or two siRNAs (#1 and #2) against ARHGAP11A plus atelocollagen (<i>red open</i> circles and squares, respectively). …”

Loss of FlnA and Fmn2 leads to a defect in cell proliferation along the ventral thoracic wall. by Gewei Lian (523268)

“…</b> The number of BrdU or Ki67 positive cells in the ventral midline of null FlnA and null FlnA+Fmn2 embryos was decreased by more than 50% in comparison with those in WT embryo (WT vs null FlnA *** = p <0.0002, WT vs null FlnA+Fmn2 *** = p <0.0008). …”

AZD8055 inhibits the proliferation and differentiation of naive CD4+ T cells in vitro. by Shurong Hu (2634826)

Presentation 1_Case Report: Full recovery in severe ParvovirusB19 myocarditis with DCM phenotype: the impact of rASD and PAB.pptx by T. Logeswaran (21495341)

“…The pressure gradient across the PAB ranged from 40 to 45 mmHg, and LVEDD decreased to a mean z-score of +3.5. Within three to six months, LVEDD normalized, and LV-EF increased to a mean of 63% (range: 57%–68%). …”

Chronic Sleep Deprivation-Induced Proteome Changes in Astrocytes of the Rat Hypothalamus by Jae-Hong Kim (124622)

“…Comparisons of the proteome profiles of hypothalamic astrocytes revealed that chronic partial SD increased (≥1.5-fold) 89 proteins and decreased (≤0.7-fold) 50 proteins; these changes in protein expression were validated by western blot or immunohistochemistry. …”

Chronic Sleep Deprivation-Induced Proteome Changes in Astrocytes of the Rat Hypothalamus by Jae-Hong Kim (124622)

“…Comparisons of the proteome profiles of hypothalamic astrocytes revealed that chronic partial SD increased (≥1.5-fold) 89 proteins and decreased (≤0.7-fold) 50 proteins; these changes in protein expression were validated by western blot or immunohistochemistry. …”

Chronic Sleep Deprivation-Induced Proteome Changes in Astrocytes of the Rat Hypothalamus by Jae-Hong Kim (124622)

“…Comparisons of the proteome profiles of hypothalamic astrocytes revealed that chronic partial SD increased (≥1.5-fold) 89 proteins and decreased (≤0.7-fold) 50 proteins; these changes in protein expression were validated by western blot or immunohistochemistry. …”

Chronic Sleep Deprivation-Induced Proteome Changes in Astrocytes of the Rat Hypothalamus by Jae-Hong Kim (124622)

“…Comparisons of the proteome profiles of hypothalamic astrocytes revealed that chronic partial SD increased (≥1.5-fold) 89 proteins and decreased (≤0.7-fold) 50 proteins; these changes in protein expression were validated by western blot or immunohistochemistry. …”

Dynamin inhibition affects secretion of other proteins. by Maaike Kockx (154125)

“…*<i>P</i><0.05 <i>v</i> Ctrl.</p>…”

Analysis of replication at unique origins. by Kelsey L. Lynch (7465649)

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”

Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)

“…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”